ArticleThe Journal of clinical and aesthetic dermatology2025
Managing Rosacea with Nanodiamond-zinc Oxide: Real-world Evidence for Reduction in Redness and Acne Lesions.
Article in The Journal of clinical and aesthetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe authors sought to observe the effect of nanodiamond-zinc oxide (ND-ZnO)-containing skincare preparations on facial erythema and acne-like lesions in subjects with rosacea or rosacea-like symptoms.
methodsAn eight-week, real-world case series was compiled, with 35 included patients who exhibited facial redness and/or papulopustular features. Participants were assigned to one of two regimens: (1) ND-ZnO-containing cream applied once daily, or (2) ND-ZnO-containing serum applied twice daily with the cream layered on in the morning. Redness was assessed via expert grading using a standardized scale, while lesion counts (inflammatory and non-inflammatory) were evaluated by a board-certified dermatologist at baseline, Week 4, and Week 8. Participants also completed a self-assessment questionnaire on skin tone and radiance.
resultsOf the participants evaluated for redness, 94.7 percent showed improvement by expert grading. Self-assessment revealed that 95 percent reported brighter, more even skin tone. Mean erythema scores decreased from 0.86 at baseline to 0.69 at Week 4 and 0.54 at Week 8. Non-inflammatory lesions declined from 22 to 1, and inflammatory lesions resolved completely by Week 8. Representative case studies confirmed visible improvement in redness, skin texture, and clarity. LIMITATIONS: The absence of a placebo control and the short duration limit generalizability and long-term assessment. Results should be confirmed in randomized controlled trials.
conclusionND-ZnO-containing skincare preparations were effective in reducing facial redness and acneiform lesions, with improvements observed across multiple skin types. These findings support their potential use in the topical management of rosacea.
Indexed as
Identifiers
40778007PMC12327563What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.